Entry Point Capital, LLC Xeris Biopharma Holdings, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 52,760 shares of XERS stock, worth $189,408. This represents 0.08% of its overall portfolio holdings.
Number of Shares
52,760
Previous 34,633
52.34%
Holding current value
$189,408
Previous $98,000
81.63%
% of portfolio
0.08%
Previous 0.06%
Shares
3 transactions
Others Institutions Holding XERS
# of Institutions
161Shares Held
60.3MCall Options Held
118KPut Options Held
45.7K-
Black Rock Inc. New York, NY10.3MShares$37.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.9MShares$28.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.35MShares$12 Million0.0% of portfolio
-
State Street Corp Boston, MA3.34MShares$12 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.88MShares$10.3 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $488M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...